Company news: Novo Nordisk

Share this article:
Novo Nordisk reported first-half gains in operating profit of 13%, along with sales growth of 11% in local currencies driven by Victoza, NovoRapid and Levemir. Victoza sales were up 253% to around $444 million while sales of modern insulins were up 10% and North American sales rose 15%.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.